Attached files
| file | filename |
|---|---|
| EX-32.1 - EXHIBIT 32.1 - BIOCRYST PHARMACEUTICALS INC | ex_245742.htm |
| EX-31.2 - EXHIBIT 31.2 - BIOCRYST PHARMACEUTICALS INC | ex_245741.htm |
| EX-31.1 - EXHIBIT 31.1 - BIOCRYST PHARMACEUTICALS INC | ex_245740.htm |
| EX-10.2 - EXHIBIT 10.2 - BIOCRYST PHARMACEUTICALS INC | ex_247204.htm |
| EX-10.1 - EXHIBIT 10.1 - BIOCRYST PHARMACEUTICALS INC | ex_247203.htm |
| 10-Q - FORM 10-Q - BIOCRYST PHARMACEUTICALS INC | bcrx20210331_10q.htm |
Exhibit 32.2
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of BioCryst Pharmaceuticals, Inc. (the “Company”) on Form 10-Q for the period ended March 31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Anthony Doyle, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:
|
1. |
The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
|
2. |
The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company. |
| /s/ Anthony Doyle | |
| Anthony Doyle | |
| Chief Financial Officer | |
| Date: May 7, 2021 |